Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 2Rectal Neoplasms 2Lymphoma 2Lung Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Small Cell 1Anus Neoplasms 1

Interventions

Cisplatin 7pembrolizumab 4Radiotherapy 3Paclitaxel 3fludarabine 2durvalumab 2aldesleukin 2Taxes 2Fluorouracil 2Cyclophosphamide 2Biopsy 2veliparib 1tremelimumab 1prednylidene 1niraparib 1fludarabine phosphate 1exifone 1entinostat 1dostarlimab 1deltacortene 1dehydroftorafur 1bintrafusp alfa protein, human 1advexin 1Tomography, X-Ray Computed 1Specimen Handling 1Radiosurgery 1Radiation 1Prednisone 1Platinum 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oropharyngeal Neoplasms × Tomography, X-Ray Computed × Clear all
NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
39 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡